Canada Pharmaceutical Market Size, Share & Trends Analysis Report By Drug Type, By Product (Branded), By Type (Prescription, OTC), By Disease (Cancer), By Route Of Administration, By Formulation, By Age Group, By End-use, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 2 Business Days
Canada Pharmaceutical Market Growth & Trends
The Canada pharmaceutical market is anticipated to reach USD 76.9 billion by 2030 and expand at a CAGR of 7.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Several driving factors influence this significant and highly regulated industry. One of the primary drivers is Canada's aging population. With a growing number of seniors, there's a heightened demand for pharmaceuticals and healthcare services. For example, medications for conditions like osteoarthritis and Alzheimer's are in high demand due to the aging demographic.
Government regulation also plays a crucial role in shaping the pharmaceutical market. Health Canada, the country's regulatory body, oversees drug safety and efficacy. For instance, the approval and regulation of prescription drugs like insulin and antibiotics ensure the quality and safety of medicines available in the market. Research and development (R&D) efforts are another crucial factor. Canada boasts a strong R&D sector, with pharmaceutical companies like Apotex and Valeo Pharma conducting innovative research. For example, developing biologic drugs for conditions like cancer and autoimmune diseases benefits patients and contributes to economic growth.
Moreover, product launches by key players in the market will further propel the Canadian pharmaceutical market growth in the forecast period. For instance, the approval of Arexvy, a respiratory syncytial virus (RSV) vaccine, for individuals aged 60 and older is a significant development in Canada's healthcare landscape. RSV is a common cause of lower respiratory tract disease (LRTD) in older adults, making this vaccine a valuable addition to the preventive measures available. This approval expands the vaccine portfolio of GSK in Canada and addresses a specific healthcare need for the aging population. Introducing Arexvy is especially noteworthy as it marks the first approval of the RSV vaccine for older adults in the country. RSV can lead to severe respiratory illnesses, and older adults are a particularly vulnerable demographic.
Canada Pharmaceutical Market Report Highlights
F. Hoffmann-La Roche Ltd
Novartis AG
GSK plc
Pfizer Inc.
Merck & Co., Inc.
AstraZeneca
Johnson & Johnson Services, Inc.
Sanofi
Eli Lilly and Company
AbbVie Inc.
Canada Pharmaceutical Market Growth & Trends
The Canada pharmaceutical market is anticipated to reach USD 76.9 billion by 2030 and expand at a CAGR of 7.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Several driving factors influence this significant and highly regulated industry. One of the primary drivers is Canada's aging population. With a growing number of seniors, there's a heightened demand for pharmaceuticals and healthcare services. For example, medications for conditions like osteoarthritis and Alzheimer's are in high demand due to the aging demographic.
Government regulation also plays a crucial role in shaping the pharmaceutical market. Health Canada, the country's regulatory body, oversees drug safety and efficacy. For instance, the approval and regulation of prescription drugs like insulin and antibiotics ensure the quality and safety of medicines available in the market. Research and development (R&D) efforts are another crucial factor. Canada boasts a strong R&D sector, with pharmaceutical companies like Apotex and Valeo Pharma conducting innovative research. For example, developing biologic drugs for conditions like cancer and autoimmune diseases benefits patients and contributes to economic growth.
Moreover, product launches by key players in the market will further propel the Canadian pharmaceutical market growth in the forecast period. For instance, the approval of Arexvy, a respiratory syncytial virus (RSV) vaccine, for individuals aged 60 and older is a significant development in Canada's healthcare landscape. RSV is a common cause of lower respiratory tract disease (LRTD) in older adults, making this vaccine a valuable addition to the preventive measures available. This approval expands the vaccine portfolio of GSK in Canada and addresses a specific healthcare need for the aging population. Introducing Arexvy is especially noteworthy as it marks the first approval of the RSV vaccine for older adults in the country. RSV can lead to severe respiratory illnesses, and older adults are a particularly vulnerable demographic.
Canada Pharmaceutical Market Report Highlights
- By disease, the cancer segment led the market with the largest revenue share of 18.1% in 2024, attributed to the increasing prevalence of cancer and the ongoing development of advanced treatments.
- The parenteral segment is set to experience the fastest growth during the forecast period, fueled by the increasing demand for injectable medications.
- By formulation, the tablets segment accounted for the largest market share in 2024 due to their convenience, affordability, and ease of administration.
- The sprays segment is anticipated to grow at the fastest CAGR from 2025 to 2030, propelled by their user-friendly nature and precise dosing capabilities.
- By end use, the hospitals segment held the largest market share in 2024, propelled by the increasing number of hospitals, leading to higher demand for pharmaceutical drugs to treat various medical conditions.
F. Hoffmann-La Roche Ltd
Novartis AG
GSK plc
Pfizer Inc.
Merck & Co., Inc.
AstraZeneca
Johnson & Johnson Services, Inc.
Sanofi
Eli Lilly and Company
AbbVie Inc.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Type
1.2.2. Product
1.2.3. Type
1.2.4. Disease
1.2.5. Route of Administration
1.2.6. Formulation
1.2.7. Age Group
1.2.8. End Use
1.2.9. Estimates and Forecast Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details of Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug Type Outlook
2.2.2. Product Outlook
2.2.3. Type Outlook
2.2.4. Disease Outlook
2.2.5. Route of Administration Outlook
2.2.6. Formulation Outlook
2.2.7. Age Group Outlook
2.2.8. End Use Outlook
2.3. Competitive Scenario
CHAPTER 3. CANADA PHARMACEUTICAL MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Canada Pharmaceutical Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.2.1. Political Landscape
3.3.2.2. Technological Landscape
3.3.2.3. Economic Landscape
CHAPTER 4. CANADA PHARMACEUTICAL MARKET: DRUG TYPE BUSINESS ANALYSIS
4.1. Drug Type Segment Dashboard
4.2. Canada Pharmaceutical Market: Drug Type Movement Analysis
4.3. Canada Pharmaceutical Market Size & Trend Analysis, By Drug Type, 2018 to 2030 (USD Billion)
4.4. Biologics & Biosimilars (Large Molecules)
4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
4.4.2. Monoclonal Antibodies
4.4.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
4.4.3. Vaccines
4.4.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
4.4.4. Cell & Gene Therapy
4.4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
4.4.5. Others
4.4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
4.5. Conventional Drugs (Small Molecules)
4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
CHAPTER 5. CANADA PHARMACEUTICAL MARKET: PRODUCT BUSINESS ANALYSIS
5.1. Product Segment Dashboard
5.2. Canada Pharmaceutical Market: Product Movement Analysis
5.3. Canada Pharmaceutical Market Size & Trend Analysis, By Product, 2018 to 2030 (USD Billion)
5.4. Branded
5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
5.5. Generics
5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
CHAPTER 6. CANADA PHARMACEUTICAL MARKET: TYPE BUSINESS ANALYSIS
6.1. Type Segment Dashboard
6.2. Canada Pharmaceutical Market: Type Movement Analysis
6.3. Canada Pharmaceutical Market Size & Trend Analysis, By Type, 2018 to 2030 (USD Billion)
6.4. Prescription
6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
6.5. OTC
6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
CHAPTER 7. CANADA PHARMACEUTICAL MARKET: DISEASE BUSINESS ANALYSIS
7.1. Disease Segment Dashboard
7.2. Canada Pharmaceutical Market: Disease Movement Analysis
7.3. Canada Pharmaceutical Market Size & Trend Analysis, By Disease, 2018 to 2030 (USD Billion)
7.4. Cardiovascular diseases
7.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.5. Cancer
7.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.6. Diabetes
7.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.7. Infectious diseases
7.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.8. Neurological Disorders
7.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.9. Respiratory diseases
7.9.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.10. Autoimmune diseases
7.10.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.11. Mental health disorders
7.11.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.12. Gastrointestinal disorders
7.12.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.13. Women’s Health Diseases
7.13.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.14. Genetic and Rare genetic diseases
7.14.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.15. Dermatological conditions
7.15.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.16. Obesity
7.16.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.17. Renal diseases
7.17.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.18. Liver conditions
7.18.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.19. Hematological disorders
7.19.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.20. Eye conditions
7.20.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.21. Infertility conditions
7.21.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.22. Endocrine disorders
7.22.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.23. Allergies
7.23.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.24. Others
7.24.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
CHAPTER 8. CANADA PHARMACEUTICAL MARKET: ROUTE OF ADMINISTRATION BUSINESS ANALYSIS
8.1. Route of Administration Segment Dashboard
8.2. Canada Pharmaceutical Market: Route of Administration Movement Analysis
8.3. Canada Pharmaceutical Market Size & Trend Analysis, By Route of Administration, 2018 to 2030 (USD Billion)
8.4. Oral
8.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
8.5. Topical
8.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
8.6. Parenteral
8.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
8.6.2. Intravenous
8.6.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
8.6.3. Intramuscular
8.6.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
8.7. Inhalations
8.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
8.8. Other Routes of Administration
8.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
CHAPTER 9. CANADA PHARMACEUTICAL MARKET: FORMULATION BUSINESS ANALYSIS
9.1. Formulation Segment Dashboard
9.2. Canada Pharmaceutical Market: Formulation Movement Analysis
9.3. Canada Pharmaceutical Market Size & Trend Analysis, By Formulation, 2018 to 2030 (USD Billion)
9.4. Tablets
9.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
9.5. Capsules
9.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
9.6. Injectable
9.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
9.7. Sprays
9.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
9.8. Suspensions
9.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
9.9. Powders
9.9.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
9.10. Other Formulations
9.10.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
CHAPTER 10. CANADA PHARMACEUTICAL MARKET: AGE GROUP BUSINESS ANALYSIS
10.1. Age Group Segment Dashboard
10.2. Canada Pharmaceutical Market: Age Group Movement Analysis
10.3. Canada Pharmaceutical Market Size & Trend Analysis, By Age Group, 2018 to 2030 (USD Billion)
10.4. Children & Adolescents
10.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
10.5. Adults
10.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
10.6. Geriatric
10.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
CHAPTER 11. CANADA PHARMACEUTICAL MARKET: END USE BUSINESS ANALYSIS
11.1. End Use Segment Dashboard
11.2. Canada Pharmaceutical Market: End Use Movement Analysis
11.3. Canada Pharmaceutical Market Size & Trend Analysis, By End Use, 2018 to 2030 (USD Billion)
11.4. Hospitals
11.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
11.5. Clinics
11.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
11.6. Others
11.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
CHAPTER 12. COMPETITIVE LANDSCAPE
12.1. Recent Developments & Impact Analysis, By Key Market Participants
12.2. Company/ Competition Categorization
12.3. Vendor Landscape
12.3.1. Key Company Heat Map Analysis, 2024
12.4. Company Profiles
12.4.1. F. Hoffmann-La Roche Ltd
12.4.1.1. Company Overview
12.4.1.2. Financial Performance
12.4.1.3. Product Benchmarking
12.4.1.4. Strategic Initiatives
12.4.2. Novartis AG
12.4.2.1. Company Overview
12.4.2.2. Financial Performance
12.4.2.3. Product Benchmarking
12.4.2.4. Strategic Initiatives
12.4.3. GSK plc
12.4.3.1. Company Overview
12.4.3.2. Financial Performance
12.4.3.3. Product Benchmarking
12.4.3.4. Strategic Initiatives
12.4.4. Pfizer Inc.
12.4.4.1. Company Overview
12.4.4.2. Financial Performance
12.4.4.3. Product Benchmarking
12.4.4.4. Strategic Initiatives
12.4.5. Merck & Co., Inc.
12.4.5.1. Company Overview
12.4.5.2. Financial Performance
12.4.5.3. Product Benchmarking
12.4.5.4. Strategic Initiatives
12.4.6. AstraZeneca
12.4.6.1. Company Overview
12.4.6.2. Financial Performance
12.4.6.3. Product Benchmarking
12.4.6.4. Strategic Initiatives
12.4.7. Johnson & Johnson Services, Inc.
12.4.7.1. Company Overview
12.4.7.2. Financial Performance
12.4.7.3. Product Benchmarking
12.4.7.4. Strategic Initiatives
12.4.8. Sanofi
12.4.8.1. Company Overview
12.4.8.2. Financial Performance
12.4.8.3. Product Benchmarking
12.4.8.4. Strategic Initiatives
12.4.9. Eli Lilly and Company
12.4.9.1. Company Overview
12.4.9.2. Financial Performance
12.4.9.3. Product Benchmarking
12.4.9.4. Strategic Initiatives
12.4.10. AbbVie Inc.
12.4.10.1. Company Overview
12.4.10.2. Financial Performance
12.4.10.3. Product Benchmarking
12.4.10.4. Strategic Initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Type
1.2.2. Product
1.2.3. Type
1.2.4. Disease
1.2.5. Route of Administration
1.2.6. Formulation
1.2.7. Age Group
1.2.8. End Use
1.2.9. Estimates and Forecast Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details of Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug Type Outlook
2.2.2. Product Outlook
2.2.3. Type Outlook
2.2.4. Disease Outlook
2.2.5. Route of Administration Outlook
2.2.6. Formulation Outlook
2.2.7. Age Group Outlook
2.2.8. End Use Outlook
2.3. Competitive Scenario
CHAPTER 3. CANADA PHARMACEUTICAL MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Canada Pharmaceutical Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.2.1. Political Landscape
3.3.2.2. Technological Landscape
3.3.2.3. Economic Landscape
CHAPTER 4. CANADA PHARMACEUTICAL MARKET: DRUG TYPE BUSINESS ANALYSIS
4.1. Drug Type Segment Dashboard
4.2. Canada Pharmaceutical Market: Drug Type Movement Analysis
4.3. Canada Pharmaceutical Market Size & Trend Analysis, By Drug Type, 2018 to 2030 (USD Billion)
4.4. Biologics & Biosimilars (Large Molecules)
4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
4.4.2. Monoclonal Antibodies
4.4.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
4.4.3. Vaccines
4.4.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
4.4.4. Cell & Gene Therapy
4.4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
4.4.5. Others
4.4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
4.5. Conventional Drugs (Small Molecules)
4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
CHAPTER 5. CANADA PHARMACEUTICAL MARKET: PRODUCT BUSINESS ANALYSIS
5.1. Product Segment Dashboard
5.2. Canada Pharmaceutical Market: Product Movement Analysis
5.3. Canada Pharmaceutical Market Size & Trend Analysis, By Product, 2018 to 2030 (USD Billion)
5.4. Branded
5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
5.5. Generics
5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
CHAPTER 6. CANADA PHARMACEUTICAL MARKET: TYPE BUSINESS ANALYSIS
6.1. Type Segment Dashboard
6.2. Canada Pharmaceutical Market: Type Movement Analysis
6.3. Canada Pharmaceutical Market Size & Trend Analysis, By Type, 2018 to 2030 (USD Billion)
6.4. Prescription
6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
6.5. OTC
6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
CHAPTER 7. CANADA PHARMACEUTICAL MARKET: DISEASE BUSINESS ANALYSIS
7.1. Disease Segment Dashboard
7.2. Canada Pharmaceutical Market: Disease Movement Analysis
7.3. Canada Pharmaceutical Market Size & Trend Analysis, By Disease, 2018 to 2030 (USD Billion)
7.4. Cardiovascular diseases
7.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.5. Cancer
7.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.6. Diabetes
7.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.7. Infectious diseases
7.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.8. Neurological Disorders
7.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.9. Respiratory diseases
7.9.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.10. Autoimmune diseases
7.10.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.11. Mental health disorders
7.11.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.12. Gastrointestinal disorders
7.12.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.13. Women’s Health Diseases
7.13.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.14. Genetic and Rare genetic diseases
7.14.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.15. Dermatological conditions
7.15.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.16. Obesity
7.16.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.17. Renal diseases
7.17.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.18. Liver conditions
7.18.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.19. Hematological disorders
7.19.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.20. Eye conditions
7.20.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.21. Infertility conditions
7.21.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.22. Endocrine disorders
7.22.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.23. Allergies
7.23.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.24. Others
7.24.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
CHAPTER 8. CANADA PHARMACEUTICAL MARKET: ROUTE OF ADMINISTRATION BUSINESS ANALYSIS
8.1. Route of Administration Segment Dashboard
8.2. Canada Pharmaceutical Market: Route of Administration Movement Analysis
8.3. Canada Pharmaceutical Market Size & Trend Analysis, By Route of Administration, 2018 to 2030 (USD Billion)
8.4. Oral
8.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
8.5. Topical
8.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
8.6. Parenteral
8.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
8.6.2. Intravenous
8.6.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
8.6.3. Intramuscular
8.6.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
8.7. Inhalations
8.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
8.8. Other Routes of Administration
8.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
CHAPTER 9. CANADA PHARMACEUTICAL MARKET: FORMULATION BUSINESS ANALYSIS
9.1. Formulation Segment Dashboard
9.2. Canada Pharmaceutical Market: Formulation Movement Analysis
9.3. Canada Pharmaceutical Market Size & Trend Analysis, By Formulation, 2018 to 2030 (USD Billion)
9.4. Tablets
9.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
9.5. Capsules
9.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
9.6. Injectable
9.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
9.7. Sprays
9.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
9.8. Suspensions
9.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
9.9. Powders
9.9.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
9.10. Other Formulations
9.10.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
CHAPTER 10. CANADA PHARMACEUTICAL MARKET: AGE GROUP BUSINESS ANALYSIS
10.1. Age Group Segment Dashboard
10.2. Canada Pharmaceutical Market: Age Group Movement Analysis
10.3. Canada Pharmaceutical Market Size & Trend Analysis, By Age Group, 2018 to 2030 (USD Billion)
10.4. Children & Adolescents
10.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
10.5. Adults
10.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
10.6. Geriatric
10.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
CHAPTER 11. CANADA PHARMACEUTICAL MARKET: END USE BUSINESS ANALYSIS
11.1. End Use Segment Dashboard
11.2. Canada Pharmaceutical Market: End Use Movement Analysis
11.3. Canada Pharmaceutical Market Size & Trend Analysis, By End Use, 2018 to 2030 (USD Billion)
11.4. Hospitals
11.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
11.5. Clinics
11.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
11.6. Others
11.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
CHAPTER 12. COMPETITIVE LANDSCAPE
12.1. Recent Developments & Impact Analysis, By Key Market Participants
12.2. Company/ Competition Categorization
12.3. Vendor Landscape
12.3.1. Key Company Heat Map Analysis, 2024
12.4. Company Profiles
12.4.1. F. Hoffmann-La Roche Ltd
12.4.1.1. Company Overview
12.4.1.2. Financial Performance
12.4.1.3. Product Benchmarking
12.4.1.4. Strategic Initiatives
12.4.2. Novartis AG
12.4.2.1. Company Overview
12.4.2.2. Financial Performance
12.4.2.3. Product Benchmarking
12.4.2.4. Strategic Initiatives
12.4.3. GSK plc
12.4.3.1. Company Overview
12.4.3.2. Financial Performance
12.4.3.3. Product Benchmarking
12.4.3.4. Strategic Initiatives
12.4.4. Pfizer Inc.
12.4.4.1. Company Overview
12.4.4.2. Financial Performance
12.4.4.3. Product Benchmarking
12.4.4.4. Strategic Initiatives
12.4.5. Merck & Co., Inc.
12.4.5.1. Company Overview
12.4.5.2. Financial Performance
12.4.5.3. Product Benchmarking
12.4.5.4. Strategic Initiatives
12.4.6. AstraZeneca
12.4.6.1. Company Overview
12.4.6.2. Financial Performance
12.4.6.3. Product Benchmarking
12.4.6.4. Strategic Initiatives
12.4.7. Johnson & Johnson Services, Inc.
12.4.7.1. Company Overview
12.4.7.2. Financial Performance
12.4.7.3. Product Benchmarking
12.4.7.4. Strategic Initiatives
12.4.8. Sanofi
12.4.8.1. Company Overview
12.4.8.2. Financial Performance
12.4.8.3. Product Benchmarking
12.4.8.4. Strategic Initiatives
12.4.9. Eli Lilly and Company
12.4.9.1. Company Overview
12.4.9.2. Financial Performance
12.4.9.3. Product Benchmarking
12.4.9.4. Strategic Initiatives
12.4.10. AbbVie Inc.
12.4.10.1. Company Overview
12.4.10.2. Financial Performance
12.4.10.3. Product Benchmarking
12.4.10.4. Strategic Initiatives
LIST OF TABLES
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Canada Pharmaceutical Market, By Drug Type, 2018 - 2030 (USD Billion)
Table 4 Canada Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
Table 5 Canada Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
Table 6 Canada Pharmaceutical Market, By Disease, 2018 - 2030 (USD Billion)
Table 7 Canada Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 8 Canada Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
Table 9 Canada Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
Table 10 Canada Pharmaceutical Market, By End Use, 2018 - 2030 (USD Billion)
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Canada Pharmaceutical Market, By Drug Type, 2018 - 2030 (USD Billion)
Table 4 Canada Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
Table 5 Canada Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
Table 6 Canada Pharmaceutical Market, By Disease, 2018 - 2030 (USD Billion)
Table 7 Canada Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 8 Canada Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
Table 9 Canada Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
Table 10 Canada Pharmaceutical Market, By End Use, 2018 - 2030 (USD Billion)
LIST OF FIGURES
Fig. 1 Market Research Process
Fig. 2 Data Triangulation Techniques
Fig. 3 Primary Research Pattern
Fig. 4 Primary Interviews
Fig. 5 Market Research Approaches
Fig. 6 Value-Chain-Based Sizing & Forecasting
Fig. 7 QFD Modeling for Market Share Assessment
Fig. 8 Market Formulation & Validation
Fig. 9 Canada Pharmaceutical Market: Market Outlook
Fig. 10 Canada Pharmaceutical Competitive Insights
Fig. 11 Parent Market Outlook
Fig. 12 Related/Ancillary Market Outlook
Fig. 13 Penetration and Growth Prospect Mapping
Fig. 14 Industry Value Chain Analysis
Fig. 15 Canada Pharmaceutical Market Driver Impact
Fig. 16 Canada Pharmaceutical Market Restraint Impact
Fig. 17 Canada Pharmaceutical Market Strategic Initiatives Analysis
Fig. 18 Canada Pharmaceutical Market: Drug Type Movement Analysis
Fig. 19 Canada Pharmaceutical Market: Drug Type Outlook and Key Takeaways
Fig. 20 Biologics & Biosimilars (Large Molecules) Market Estimates and Forecast, 2018 - 2030
Fig. 21 Monoclonal Antibodies Market Estimates and Forecast, 2018 - 2030
Fig. 22 Vaccines Market Estimates and Forecast, 2018 - 2030
Fig. 23 Cell & Gene Therapy Market Estimates and Forecast, 2018 - 2030
Fig. 24 Others Market Estimates and Forecast, 2018 - 2030
Fig. 25 Conventional Drugs (Small Molecules) Market Estimates and Forecast, 2018 - 2030
Fig. 26 Canada Pharmaceutical Market: Product Movement Analysis
Fig. 27 Canada Pharmaceutical Market: Product Outlook and Key Takeaways
Fig. 28 Branded Market Estimates and Forecast, 2018 - 2030
Fig. 29 Generics Market Estimates and Forecast, 2018 - 2030
Fig. 30 Canada Pharmaceutical Market: Type Movement Analysis
Fig. 31 Canada Pharmaceutical Market: Type Outlook and Key Takeaways
Fig. 32 Prescription Market Estimates and Forecast, 2018 - 2030
Fig. 33 OTC Market Estimates and Forecast, 2018 - 2030
Fig. 34 Canada Pharmaceutical Market: Disease Movement Analysis
Fig. 35 Canada Pharmaceutical Market: Disease Outlook and Key Takeaways
Fig. 36 Cardiovascular diseases Market Estimates and Forecast, 2018 - 2030
Fig. 37 Cancer Market Estimates and Forecast, 2018 - 2030
Fig. 38 Diabetes Market Estimates and Forecast, 2018 - 2030
Fig. 39 Infectious diseases Market Estimates and Forecast, 2018 - 2030
Fig. 40 Neurological disorders Market Estimates and Forecast, 2018 - 2030
Fig. 41 Respiratory diseases Market Estimates and Forecast, 2018 - 2030
Fig. 42 Autoimmune diseases Market Estimates and Forecast, 2018 - 2030
Fig. 43 Mental health disorders Market Estimates and Forecast, 2018 - 2030
Fig. 44 Gastrointestinal disorders Market Estimates and Forecast, 2018 - 2030
Fig. 45 Women’s Health Diseases Market Estimates and Forecast, 2018 - 2030
Fig. 46 Genetic and Rare genetic diseases Market Estimates and Forecast, 2018 - 2030
Fig. 47 Dermatological conditions Market Estimates and Forecast, 2018 - 2030
Fig. 48 Obesity Market Estimates and Forecast, 2018 - 2030
Fig. 49 Renal diseases Market Estimates and Forecast, 2018 - 2030
Fig. 50 Liver conditions Market Estimates and Forecast, 2018 - 2030
Fig. 51 Hematological disorders Market Estimates and Forecast, 2018 - 2030
Fig. 52 Eye conditions Market Estimates and Forecast, 2018 - 2030
Fig. 53 Infertility conditions Market Estimates and Forecast, 2018 - 2030
Fig. 54 Endocrine disorders Market Estimates and Forecast, 2018 - 2030
Fig. 55 Allergies Market Estimates and Forecast, 2018 - 2030
Fig. 56 Others Market Estimates and Forecast, 2018 - 2030
Fig. 57 Canada Pharmaceutical Market: Route of Administration Movement Analysis
Fig. 58 Canada Pharmaceutical Market: Route of Administration Outlook and Key Takeaways
Fig. 59 Oral Market Estimates and Forecast, 2018 - 2030
Fig. 60 Topical Market Estimates and Forecast, 2018 - 2030
Fig. 61 Parenteral Market Estimates and Forecast, 2018 - 2030
Fig. 62 Intravenous Market Estimates and Forecast, 2018 - 2030
Fig. 63 Intramuscular Market Estimates and Forecast, 2018 - 2030
Fig. 64 Inhalations Market Estimates and Forecast, 2018 - 2030
Fig. 65 Other Routes of Administration Market Estimates and Forecast, 2018 - 2030
Fig. 66 Canada Pharmaceutical Market: Formulation Movement Analysis
Fig. 67 Canada Pharmaceutical Market: Formulation Outlook and Key Takeaways
Fig. 68 Tablets Market Estimates and Forecast, 2018 - 2030
Fig. 69 Capsules Market Estimates and Forecast, 2018 - 2030
Fig. 70 Injectable Market Estimates and Forecast, 2018 - 2030
Fig. 71 Sprays Market Estimates and Forecast, 2018 - 2030
Fig. 72 Suspensions Market Estimates and Forecast, 2018 - 2030
Fig. 73 Powders Market Estimates and Forecast, 2018 - 2030
Fig. 74 Other Formulations Market Estimates and Forecast, 2018 - 2030
Fig. 75 Canada Pharmaceutical Market: Age Group Movement Analysis
Fig. 76 Canada Pharmaceutical Market: Age Group Outlook and Key Takeaways
Fig. 77 Children & Adolescents Market Estimates and Forecast, 2018 - 2030
Fig. 78 Adults Market Estimates and Forecast, 2018 - 2030
Fig. 79 Geriatric Market Estimates and Forecast, 2018 - 2030
Fig. 80 Canada Pharmaceutical Market: End Use Movement Analysis
Fig. 81 Canada Pharmaceutical Market: End Use Outlook and Key Takeaways
Fig. 82 Hospitals Market, 2018 - 2030 (USD Billion)
Fig. 83 Clinics Market, 2018 - 2030 (USD Billion)
Fig. 84 Others Market, 2018 - 2030 (USD Billion)
Fig. 1 Market Research Process
Fig. 2 Data Triangulation Techniques
Fig. 3 Primary Research Pattern
Fig. 4 Primary Interviews
Fig. 5 Market Research Approaches
Fig. 6 Value-Chain-Based Sizing & Forecasting
Fig. 7 QFD Modeling for Market Share Assessment
Fig. 8 Market Formulation & Validation
Fig. 9 Canada Pharmaceutical Market: Market Outlook
Fig. 10 Canada Pharmaceutical Competitive Insights
Fig. 11 Parent Market Outlook
Fig. 12 Related/Ancillary Market Outlook
Fig. 13 Penetration and Growth Prospect Mapping
Fig. 14 Industry Value Chain Analysis
Fig. 15 Canada Pharmaceutical Market Driver Impact
Fig. 16 Canada Pharmaceutical Market Restraint Impact
Fig. 17 Canada Pharmaceutical Market Strategic Initiatives Analysis
Fig. 18 Canada Pharmaceutical Market: Drug Type Movement Analysis
Fig. 19 Canada Pharmaceutical Market: Drug Type Outlook and Key Takeaways
Fig. 20 Biologics & Biosimilars (Large Molecules) Market Estimates and Forecast, 2018 - 2030
Fig. 21 Monoclonal Antibodies Market Estimates and Forecast, 2018 - 2030
Fig. 22 Vaccines Market Estimates and Forecast, 2018 - 2030
Fig. 23 Cell & Gene Therapy Market Estimates and Forecast, 2018 - 2030
Fig. 24 Others Market Estimates and Forecast, 2018 - 2030
Fig. 25 Conventional Drugs (Small Molecules) Market Estimates and Forecast, 2018 - 2030
Fig. 26 Canada Pharmaceutical Market: Product Movement Analysis
Fig. 27 Canada Pharmaceutical Market: Product Outlook and Key Takeaways
Fig. 28 Branded Market Estimates and Forecast, 2018 - 2030
Fig. 29 Generics Market Estimates and Forecast, 2018 - 2030
Fig. 30 Canada Pharmaceutical Market: Type Movement Analysis
Fig. 31 Canada Pharmaceutical Market: Type Outlook and Key Takeaways
Fig. 32 Prescription Market Estimates and Forecast, 2018 - 2030
Fig. 33 OTC Market Estimates and Forecast, 2018 - 2030
Fig. 34 Canada Pharmaceutical Market: Disease Movement Analysis
Fig. 35 Canada Pharmaceutical Market: Disease Outlook and Key Takeaways
Fig. 36 Cardiovascular diseases Market Estimates and Forecast, 2018 - 2030
Fig. 37 Cancer Market Estimates and Forecast, 2018 - 2030
Fig. 38 Diabetes Market Estimates and Forecast, 2018 - 2030
Fig. 39 Infectious diseases Market Estimates and Forecast, 2018 - 2030
Fig. 40 Neurological disorders Market Estimates and Forecast, 2018 - 2030
Fig. 41 Respiratory diseases Market Estimates and Forecast, 2018 - 2030
Fig. 42 Autoimmune diseases Market Estimates and Forecast, 2018 - 2030
Fig. 43 Mental health disorders Market Estimates and Forecast, 2018 - 2030
Fig. 44 Gastrointestinal disorders Market Estimates and Forecast, 2018 - 2030
Fig. 45 Women’s Health Diseases Market Estimates and Forecast, 2018 - 2030
Fig. 46 Genetic and Rare genetic diseases Market Estimates and Forecast, 2018 - 2030
Fig. 47 Dermatological conditions Market Estimates and Forecast, 2018 - 2030
Fig. 48 Obesity Market Estimates and Forecast, 2018 - 2030
Fig. 49 Renal diseases Market Estimates and Forecast, 2018 - 2030
Fig. 50 Liver conditions Market Estimates and Forecast, 2018 - 2030
Fig. 51 Hematological disorders Market Estimates and Forecast, 2018 - 2030
Fig. 52 Eye conditions Market Estimates and Forecast, 2018 - 2030
Fig. 53 Infertility conditions Market Estimates and Forecast, 2018 - 2030
Fig. 54 Endocrine disorders Market Estimates and Forecast, 2018 - 2030
Fig. 55 Allergies Market Estimates and Forecast, 2018 - 2030
Fig. 56 Others Market Estimates and Forecast, 2018 - 2030
Fig. 57 Canada Pharmaceutical Market: Route of Administration Movement Analysis
Fig. 58 Canada Pharmaceutical Market: Route of Administration Outlook and Key Takeaways
Fig. 59 Oral Market Estimates and Forecast, 2018 - 2030
Fig. 60 Topical Market Estimates and Forecast, 2018 - 2030
Fig. 61 Parenteral Market Estimates and Forecast, 2018 - 2030
Fig. 62 Intravenous Market Estimates and Forecast, 2018 - 2030
Fig. 63 Intramuscular Market Estimates and Forecast, 2018 - 2030
Fig. 64 Inhalations Market Estimates and Forecast, 2018 - 2030
Fig. 65 Other Routes of Administration Market Estimates and Forecast, 2018 - 2030
Fig. 66 Canada Pharmaceutical Market: Formulation Movement Analysis
Fig. 67 Canada Pharmaceutical Market: Formulation Outlook and Key Takeaways
Fig. 68 Tablets Market Estimates and Forecast, 2018 - 2030
Fig. 69 Capsules Market Estimates and Forecast, 2018 - 2030
Fig. 70 Injectable Market Estimates and Forecast, 2018 - 2030
Fig. 71 Sprays Market Estimates and Forecast, 2018 - 2030
Fig. 72 Suspensions Market Estimates and Forecast, 2018 - 2030
Fig. 73 Powders Market Estimates and Forecast, 2018 - 2030
Fig. 74 Other Formulations Market Estimates and Forecast, 2018 - 2030
Fig. 75 Canada Pharmaceutical Market: Age Group Movement Analysis
Fig. 76 Canada Pharmaceutical Market: Age Group Outlook and Key Takeaways
Fig. 77 Children & Adolescents Market Estimates and Forecast, 2018 - 2030
Fig. 78 Adults Market Estimates and Forecast, 2018 - 2030
Fig. 79 Geriatric Market Estimates and Forecast, 2018 - 2030
Fig. 80 Canada Pharmaceutical Market: End Use Movement Analysis
Fig. 81 Canada Pharmaceutical Market: End Use Outlook and Key Takeaways
Fig. 82 Hospitals Market, 2018 - 2030 (USD Billion)
Fig. 83 Clinics Market, 2018 - 2030 (USD Billion)
Fig. 84 Others Market, 2018 - 2030 (USD Billion)
